ANTIBODIES

Contributor Information
- Name Ayham Alnabulsi
- Institute Vertebrate Antibodies Limited
Tool Details
- Tool name: Anti-Cytochrome P450 2A6, 2A7, 2A13 [F16 P2 D8]
- Clone: F16 P2 D8
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; IHC ; WB
- Strain: Balb/c
- Description: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
- Immunogen: ovalbumin-conjugated synthetic peptide RNYTMSFLPR. CYP2A6, CYP2A7and CYP2A13 have the same c-terminal sequence. (C-terminal sequence identical in human and rhesus macaque)
- Isotype: IgG1 kappa
- Research area: Cancer; Tissue-specific biology; Cell signaling and signal transduction; Metabolism
- For Research Use Only
Target Details
- Target: Cytochrome P450 2A6, 2A7and 2A13 (CYP2A6, CYP2A7, CYP2A13)
- Target background: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Application Details
- Application: ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15ðC to -25ðC
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162.
- • Profiling the expression of cytochrome P450 in breast cancer.
- • Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
- • Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
- • Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
- • Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.